CASE REPORTS
JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature.

Acanthosis nigricans (AN) is a skin disorder characterized by focal or diffuse hyperkeratosis symmetric hyperpigmentation of the skin and oral cavity mucosa. Various neoplasms, especially gastrointestinal adenocarcinomas are associated with acanthosis nigricans (AN malignant). Chemotherapy may cause regression of skin lesions. The etiology of AN is not clear. A role of growth factors such as melanocyte stimulating hormone alpha, transforming growth factor alpha, and insulin-like growth factor 1 has been discussed. Two cases of AN have been reported in this paper. Both have been associated with gastric adenocarcinoma. In the first case skin lesions were sensitive to chemotherapy (until cancer progression), while in the second case treatment had to be discontinued because of cardiotoxity without regression of skin lesions.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app